Source: Getty Images Drs Uzzo, Chung, and Croll of Fox Chase Cancer Center at Temple University Health discuss top presentations from the ASCO Genitourinary Cancers Symposium 2026. The American ...

The median OS was 28 months with abiraterone-prednisone, 37 months with olaparib alone, and 68 months with abiraterone-prednisone-olaparib. In patients with metastatic castration-resistant prostate ...

The median overall survival was 38.21 months with radium-223 plus enzalutamide and 32.62 months with enzalutamide alone. For patients with metastatic castration-resistant prostate cancer (mCRPC) with ...

Investigators assessed shear wave elastography (SWE) in detecting subclinical renal damage in patients with LN currently in clinical remission.

More patients receiving obinutuzumab versus placebo had primary end point of SLE Responder Index 4. (HealthDay News) — For patients with systemic lupus erythematosus (SLE), obinutuzumab, a ...

In this retrospective study, researchers sought to determine the efficacy, safety, and effectiveness of a reduced ARSI dose compared to a full dose in non-metastatic castration-resistant prostate ...

Increase from 0.16 to 0.44 new monthly dispensations per 1,000 people reported between January 2016 and June 2024. (HealthDay News) — During the COVID-19 pandemic, rates of new stimulant prescriptions ...

(HealthDay News) — Poor childhood oral health is associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD) in adulthood, according to a study published in the April 1 issue ...

Policy implementation linked to increase of 5.3 transplants per 1,000 listings in interrupted time series analysis. (HealthDay News) — Implementation of an Organ Procurement and Transplantation ...

Adults with overweight or obesity regain much of their lost weight after cessation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a re ...

Authors say individuals with COVID-19, particularly those at high risk for kidney disease, may need additional monitoring of kidney function.

The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.